In Phase II of its sodium reduction initiative, the FDA is setting new targets to improve overall health through voluntary industry compliance and enhanced consumer awareness. Learn more.
This email was sent to you by the Informa Markets Division of Informa PLC (Privacy Policy). Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
If you do not wish to receive further information from us, please click here. Alternatively, to contact our data services team to have your details or preferences updated please email imdatateam@informa.com.
